|
|
 Previous Article | Table of Contents | Next Article 
Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-
polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in
other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
A Wellmann, T Otsuki, M Vogelbruch, HM Clark, ES Jaffe and M Raffeld
Hematopathology Section, National Cancer Institute, National Institutes of
Health, Bethesda, MD 20892, USA.
The t(2;5)(p23;q35) translocation is associated with a high percentage of
anaplastic large-cell lymphomas (ALCL) of T- or null-cell phenotype. This
translocation was recently cloned and results in the fusion of the
nucleophosmin gene (NPM) on chromosome 5q35 to a novel tyrosine kinase-
encoding gene designated anaplastic lymphoma kinase (ALK) on chromosome
2p23. Using a sensitive and specific reverse transcription-polymerase chain
reaction (RT-PCR) assay to detect the NPM/ALK fusion transcript, we
assessed the involvement of NPM/ALK in a series of histologically and
immunohistochemically confirmed ALCL, in non-ALCL aggressive non- Hodgkin's
lymphomas of T-cell phenotype, and in Hodgkin's disease (HD) to better
define the morphologic spectrum of disease associated with this
translocation. Twenty-four cases of ALCL were selected on the basis of CD30
positivity and histologic features. Seventeen cases presented as classical
nodal and extranodal disease, four cases presented as primary cutaneous
disease, and three were associated with human immunodeficiency virus (HIV)
infection. As ALCL may show overlapping histology with both HD and other
aggressive non-Hodgkin's lymphomas, particularly of T-cell phenotype
(T-NHL), we also studied 34 cases of HD and 19 of T-NHL. NPM/ALK chimeric
transcripts of identical size were detected in 11 of the 24 (46%) cases of
ALCL. NPM/ALK fusion transcripts were found in 11 of 17 (65%) classical
ALCL cases but were not detected in the four primary cutaneous cases of
ALCL or in the three HIV-related ALCL cases. In addition, NPM/ALK
transcripts were not detected in any of the 34 cases of HD or in the 19
cases of T-NHL. These data indicate that NPM/ALK fusion transcripts occur
in a high percentage of classical nodal ALCL (65%). In addition, these data
strongly suggest that ALCL, as defined in this study, is not
pathogenetically related to either HD disease or the majority of other
types of aggressive T-NHL. This is a US government work. There are no
restrictions on its use.
Volume 86,
Issue 6,
pp. 2321-2328,
09/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Ravandi, M. Talpaz, and Z. Estrov
Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies
Clin. Cancer Res.,
February 1, 2003;
9(2):
535 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Kutok and J. C. Aster
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2002;
20(17):
3691 - 3702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bonvini, T. Gastaldi, B. Falini, and A. Rosolen
Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin
Cancer Res.,
March 1, 2002;
62(5):
1559 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik
Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma
J. Immunol.,
January 1, 2002;
168(1):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Maes, V. Vanhentenrijk, I. Wlodarska, J. Cools, B. Peeters, P. Marynen, and C. De Wolf-Peeters
The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells
Am. J. Pathol.,
June 1, 2001;
158(6):
2185 - 2193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Camilleri-Broet, J. Audouin, C. Ferme, J. Briere, K. Pulford, P. Gaulard, M. Divine, E. Macintyre, G. Delsol, and F. Berger
ALK is not expressed in Hodgkin disease
Blood,
March 15, 2001;
97(6):
1901 - 1902.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood,
December 1, 2000;
96(12):
3681 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Touriol, C. Greenland, L. Lamant, K. Pulford, F. Bernard, T. Rousset, D. Y. Mason, and G. Delsol
Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
Blood,
May 15, 2000;
95(10):
3204 - 3207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Pfeifer, E. Levi, T. Petrogiannis-Haliotis, L. Lehmann, Z. Wang, and M. E. Kadin
A Murine Xenograft Model for Human CD30+ Anaplastic Large Cell Lymphoma : Successful Growth Inhibition with an Anti-CD30 Antibody (HeFi-1)
Am. J. Pathol.,
October 1, 1999;
155(4):
1353 - 1359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood,
May 15, 1999;
93(10):
3167 - 3215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, N. Dastugue, K. Pulford, G. Delsol, and B. Mariame
A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation
Blood,
May 1, 1999;
93(9):
3088 - 3095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al.
ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum
Am. J. Pathol.,
September 1, 1998;
153(3):
875 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beylot-Barry, A. Groppi, B. Vergier, K. Pulford, J.P. Merlio, and t. French Study Group of Cutaneous Lymphoma
Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations
Blood,
June 15, 1998;
91(12):
4668 - 4676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Benharroch, Z. Meguerian-Bedoyan, L. Lamant, C. Amin, L. Brugieres, M.-J. Terrier-Lacombe, E. Haralambieva, K. Pulford, S. Pileri, S. W. Morris, et al.
ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of Morphology
Blood,
March 15, 1998;
91(6):
2076 - 2084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Teruya-Feldstein, E. S. Jaffe, P. R. Burd, H. Kanegane, D. W. Kingma, W. H. Wilson, D. L. Longo, and G. Tosato
The Role of Mig, the Monokine Induced by Interferon-gamma , and IP-10, the Interferon-gamma -Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease
Blood,
November 15, 1997;
90(10):
4099 - 4105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Rubnitz and W. M. Crist
Molecular Genetics of Childhood Cancer: Implications for Pathogenesis, Diagnosis, and Treatment
Pediatrics,
July 1, 1997;
100(1):
101 - 108.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Delsol, L. Lamant, B. Mariame, K. Pulford, N. Dastugue, P. Brousset, F. Rigal-Huguet, T. Al Saati, D. P. Cerretti, S. W. Morris, et al.
A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation
Blood,
March 1, 1997;
89(5):
1483 - 1490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mathew, W. G. Sanger, D. D. Weisenburger, M. Valentine, V. Valentine, D. Pickering, C. Higgins, M. Hess, X. Cui, D. K. Srivastava, et al.
Detection of the t(2; 5)(p23; q35) and NPM-ALK Fusion in Non-Hodgkin's Lymphoma by Two-Color Fluorescence In Situ Hybridization
Blood,
March 1, 1997;
89(5):
1678 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Pulford, L. Lamant, S. W. Morris, L. H. Butler, K. M. Wood, D. Stroud, G. Delsol, and D. Y. Mason
Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1
Blood,
February 15, 1997;
89(4):
1394 - 1404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Krenacs, A. Wellmann, L. Sorbara, A. W. Himmelmann, E. Bagdi, E. S. Jaffe, and M. Raffeld
Cytotoxic Cell Antigen Expression in Anaplastic Large Cell Lymphomas of T- and Null-Cell Type and Hodgkin's Disease: Evidence for Distinct Cellular Origin
Blood,
February 1, 1997;
89(3):
980 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
